GleamWall
中文EN

CVSI CV Sciences, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1510964 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-12.9%
TTM net income YoY-16.2%
TTM EPS YoY—
Revenue 3-yr CAGR-8.0%
Net income 3-yr CAGR—

Margins

Gross margin49.5%
Operating margin-2.5%
Net margin-13.7%
FCF margin-1.5%
EBITDA margin-1.8%

Returns

ROE-90.1%
ROA-25.6%
ROIC (approx.)-12.3%
Asset turnover1.86x

Leverage & solvency

Liabilities / assets64.7%
Debt / equity0.00x
Current ratio1.18x
Interest coverage-1.42x

Cash quality & payout

Operating cash flow / net income0.10x
Accruals ratio-23.0%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$13.79M$15.71M
Cost of revenue$7.04M$8.54M
Gross profit$6.75M$7.17M
R&D expense$122,000$118,000
SG&A expense$7.62M$9.24M
Operating income-$470,000-$2.19M
Interest expense$517,000$212,000
Pretax income-$949,000-$2.40M
Income tax$9,000-$8,000
Net income-$958,000-$2.39M
EBITDA-$278,000-$1.86M
EPS (basic)-0.01-0.01
EPS (diluted)-0.01-0.01
Weighted avg. shares (diluted)184.26M175.59M
Balance sheet
Cash & equivalents$278,000$454,000
Receivables$402,000$522,000
Inventory$4.09M$4.90M
Current assets$5.13M$6.24M
PP&E, net$344,000$399,000
Goodwill$1.01M$971,000
Intangibles$76,000$93,000
Total assets$6.96M$7.93M
Current liabilities$5.00M$6.11M
Short-term debt$1.26M$677,000
Long-term debt$387,000$0
Total debt$1.65M$677,000
Total liabilities$5.49M$6.13M
Shareholders' equity$1.47M$1.79M
Net debt$1.37M$223,000
Shares outstanding184.26M184.26M
Cash flow statement
Operating cash flow-$407,000-$861,000
Capital expenditure$109,000$18,000
Free cash flow-$516,000-$879,000
Investing cash flow-$109,000-$28,000
Financing cash flow$337,000$32,000
Depreciation & amortization$192,000$334,000
Stock-based compensation$497,000$258,000

Free plan shows the latest 2 periods; Pro shows all 15 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.